Accumetrics' next-gen VerifyNow II System lands CE Mark approval for sale in European markets, anticipating commercial launch early this year.
Accumetrics won CE Mark approval in the European Union for its next-generation VerifyNow II System, a device designed for point-of-care measurement of platelet reactivity to antiplatelet agents.
The regulatory is a big win for Accumentrics and validation of the clinical value of platelet reactivity testing, according to the company, which expects to expand market opportunities for the VerifyNow System in surgical and interventional cardiology patients, according to the press release.
Covidien’s 3-year study results showing positive outcomes for its Urgent PC Neuromodulation system in...
NEC Display Solutions wins 510(k) clearance for its 21-inch medical monitor systems.
J&J's former head of global cardiology makes the jump to CEO at Itamar Medical
Sunshine Heart raises $1.5 million of a hoped-for $25.5 million equity funding round.
J&J subsidiary Lifescan asks the courts to ban Shasta from using its logo, saying problems with...